Formulations of the combo vaccines prompted robust immune responses against influenza A, influenza B, and SARS-CoV-2.
The company expects an FDA decision in the first quarter of 2024.
The weekly proportion of outpatient visits for influenza-like illness, flu hospitalizations, and flu deaths all peaked between the 90th and 98th percentile.
Previously vaccinated children in a county with the greatest COVID-19 severity had a lower predicted probability of receiving a flu vaccine than those in a county with the lowest severity.
The company said a combo vaccine could streamline immunization for consumers and health providers and make it easier for people to follow public health recommendations.
A naturally occurring Yamagata lineage flu B virus hasn't been confirmed since March 2020 during the early COVID pandemic months.
The campaign portrays the flu shot as a way to lessen severity of illness, and not necessarily prevent the virus.
Groups announced new clinical trials and more support for universal flu, MERS, and mpox vaccines.
Vaccine effectiveness against hospitalization was estimated at 52%, including 55% against those related to the H1N1 strain.
A study found that the recombinant influenza vaccine provided better protection against hospitalization than the standard-dose vaccine.